Pentavalent antimony complexes, such as sodium stibogluconate and sodium antimony gluconate (SAG), are still the first choice for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis, or kala-azar. Although the requirement of a somewhat functional immune system for the antileishmanial action of antimony was reported previously, the cellular and molecular mechanism of action of SAG was not clear. Herein, we show that SAG induces extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 phosphorylation through phosphoinositide 3-kinase (PI3K), protein kinase C, and Ras activation and p38 mitogen-activated protein kinase (MAPK) phosphorylation through PI3K and Akt activation. ERK-1 and ERK-2 activation results in an increase in the production of reactive oxygen species (ROS) 3 to 6 h after SAG treatment, while p38 MAPK activation and subsequent tumor necrosis factor alpha release result in the production of nitric oxide (NO) 24 h after SAG treatment. Thus, this study has provided the first evidence that SAG treatment induces activation of some important components of the intracellular signaling pathway, which results in an early wave of ROS-dependent parasite killing and a stronger late wave of NO-dependent parasite killing. This opens up the possibility of this metalloid chelate being used in the treatment of various diseases either alone or in combination with other drugs and vaccines.
Pentavalent antimony complexes, such as sodium stibogluconate and sodium antimony gluconate (SAG), are still the first choice for chemotherapy against various forms of leishmaniasis, including visceral leishmaniasis, or kala-azar. Although the requirement of a somewhat functional immune system for the antileishmanial action of antimony was reported previously, the cellular and molecular mechanism of action of SAG was not clear. Herein, we show that SAG induces extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 phosphorylation through phosphoinositide 3-kinase (PI3K), protein kinase C, and Ras activation and p38 mitogen-activated protein kinase (MAPK) phosphorylation through PI3K and Akt activation. ERK-1 and ERK-2 activation results in an increase in the production of reactive oxygen species (ROS) 3 to 6 h after SAG treatment, while p38 MAPK activation and subsequent tumor necrosis factor alpha release result in the production of nitric oxide (NO) 24 h after SAG treatment. Thus, this study has provided the first evidence that SAG treatment induces activation of some important components of the intracellular signaling pathway, which results in an early wave of ROS-dependent parasite killing and a stronger late wave of NO-dependent parasite killing. This opens up the possibility of this metalloid chelate being used in the treatment of various diseases either alone or in combination with other drugs and vaccines.
Visceral leishmaniasis, caused by Leishmania donovani, is fatal if left untreated. The pentavalent antimony (Sb V ) compound urea stibamine first emerged as an effective chemotherapeutic agent against Indian kala-azar (6) . Although different forms of pentavalent antimony complexes (chelates, i.e., Sb V chelated to an organic backbone), namely, sodium stibogluconate (Pentostam) and meglumine antimoniate (Glucantime), are still the first choice for treatment of leishmaniases (21, 42) , their mechanism of action is still largely unknown. Previous studies indicated that sodium antimony gluconate (SAG) failed to act in immunocompromised hosts, such as patients who are suffering from AIDS or receiving immunosuppressive agents (17, 38) and nude (36) and severe combined immunodeficient (SCID) mice (15) . Several studies have shown that endogenous interleukin-2 (IL-2) (34), IL-4 (1, 43) , and IL-12 (41) influence the effectiveness of chemotherapy with pentavalent antimony. These findings are inclined to indicate the requirement of a somewhat functional T-cell compartment for SAG action. Moreover, SAG has been found to inhibit selective protein tyrosine phosphatases (Src homology 2 domain-containing tyrosine phosphatase 1 [SHP1] and SHP2) in vitro and augment cytokine signaling and responses in hematopoietic cell lines (46) , suggesting the role of phosphatases and possibly other signal transduction pathways in SAG-induced control of Leishmania infection. In addition, the dose of SAG that kills the axenic amastigotes in vitro is 50 times higher than the concentration of the drug required for killing the parasite within macrophages (Ms) (23) , suggesting host cell activation as an integral component of SAG-induced antileishmanial effects. Moreover, SAG synergizes with alpha interferon (IFN-␣) to activate STAT1 to kill IFN-␣-resistant human cancer cell lines, like WM9 (melanoma), SW620 (colon carcinoma), U266 (multiple myeloma), MDA231 (prostate cancer), etc., in vitro (56) . These studies indicate that this metalloid chelate might modulate a number of signaling events. Therefore, we assessed whether SAG modulates the signal transduction pathways in macrophages to kill the intracellular parasites. Herein, we report for the first time that SAG triggers activation of phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs) coupled with the activation of the microbicidal mechanism of M, which ultimately leads to the elimination of the intracellular L. donovani parasites. (50) parasites were used during the course of this investigation. Amastigotes obtained from spleens of infected hamsters were cultured in M199 containing 20% (vol/vol) heat-inactivated FBS supplemented with 100 IU/ml of penicillin and 100 g/ml of streptomycin at 22°C to obtain promastigotes (11) . Promastigotes were grown in fresh M199 containing 10% (vol/vol) heat-inactivated FBS for 3 to 5 days at 22°C before further experimentation.
BALB/c and C57BL/6 (wild-type and inducible nitric oxide synthase-deficient [iNOS Ϫ / Ϫ ]) mice, originally obtained from Jackson Laboratories, Bar Harbor, ME, and reared in the institute animal facilities, were used for experimental purposes with prior approval of the animal ethics committee.
Ms were isolated from mice 36 to 48 h after injection (intraperitoneal) with 2% (wt/vol) hydrolyzed starch by peritoneal lavage with ice-cold phosphatebuffered saline. Cells were washed and cultured for 18 to 24 h (for adherence) in RPMI 1640 (supplemented with 100 IU/ml of penicillin and 100 g/ml of streptomycin) containing 10% (vol/vol) heat-inactivated FBS (RPMI-FBS) at 37°C at 5% CO 2 in air in tissue culture petri dishes of 65 mm in diameter (Tarson India Ltd.), following which culture medium was washed off and fresh RPMI-FBS was added. About 1 ϫ 10 6 Ms were cultured in 1 ml of RPMI-FBS. In some experiments, 5 ϫ 10 5 Ms were maintained on 22-mm by 22-mm cover glass placed in plastic petri dishes.
Infection of Ms and determination of intracellular parasite numbers. During the course of this study, Ms were infected with promastigotes at a M-toparasite ratio of 1:10 in RPMI-FBS, as described elsewhere (11) . After 4 h of incubation at 37°C at 5% CO 2 in air, unbound parasites were washed off with RPMI and Ms were then maintained in RPMI-FBS for 22 h at 37°C at 5% CO 2 in air. Intracellular parasite numbers were enumerated in Giemsa-stained preparations of samples, as described elsewhere (11, 51) .
Treatments. At 22 h postinfection, the Ms were treated with SAG at a concentration of 10 g/ml, because this is the highest attainable serum concentration of the drug during chemotherapy of kala-azar patients (4, 46) and we have also previously demonstrated the drug to be cytotoxic in vitro above 10 g/ml (13) . In some experiments, cells were treated with the PI3K inhibitor wortmannin (1 M) (22) , the PKC inhibitor calphostin C (50 nM) (24) , the Ras inhibitor mevastatin (5 M) (20) , the p38 MAPK inhibitor SB203580 (5 M) (47), the MEK-1/MEK-2 inhibitor U0126 (1 M) (16), L-NMMA (0.4 mM) (18) , or anti-TNF-␣ Ab (10 g/ml) for 1 h prior to SAG treatment (10 g/ml) or were treated with NAC (5 mM) (49) along with SAG. The doses of inhibitors mentioned above were found to be nontoxic and were used by others previously (16, 18, 20, 22, 24, 47, 49) . We also observed that wortmannin, calphostin C, mevastatin, SB203580, U0126, L-NMMA, and TNF-␣ Ab were not cytotoxic to Ms, as evidenced by an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay and unaltered M morphology at the above-mentioned doses (data not shown). NAC at the above-mentioned reported dose was found to be nontoxic even after 18 h, as determined by trypan blue exclusion staining.
Measurement of ROS.
To monitor the level of reactive oxygen species (ROS) (including superoxide, hydrogen peroxide, and other reactive oxygen intermediates) produced within the cells, the cell-permeable, nonpolar, H 2 O 2 -sensitive probe DCFDA was used (53) . Extent of H 2 O 2 generation was defined as ROS generation for our convenience. Uninfected Ms and infected Ms (I-Ms), untreated or treated with SAG for various durations, were pretreated in some experiments with wortmannin, calphostin C, mevastatin, U0126, or SB203580 for 1 h or treated with NAC along with SAG. The cells were harvested in Hanks balanced salt solution (HBSS). Finally, 1 ϫ 10 6 cells were placed in 1 ml of HBSS, pulsed with DCFDA (5 M) for 20 to 30 min at 37°C in the dark, and then washed twice with HBSS; the relative fluorescence was measured by fluorimetry with a fluorimeter (Hitachi) (excitation at 505 nm and emission at 525 nm at a slit size of 1 nm). For each experimental sample, fluorimetric measurements were performed in triplicate and expressed as fluorescent intensity units/ 10 6 cells.
Measurement of NO.
Nitric oxide (NO) generation in response to SAG treatment of Ms or I-Ms was monitored by Griess reaction as described previously (18, 19) . In some experiments, the cells were treated with wortmannin, calphostin C, mevastatin, U0126, SB203580, anti-TNF-␣, or L-NMMA for 1 h prior to SAG treatment. The amount of nitrite accumulated was calculated from a standard curve constructed with different concentrations of sodium nitrite, and the concentration of nitrite accumulated was expressed as M nitrite.
Preparation of cell lysates and Western blot analysis. Uninfected Ms or I-Ms, either untreated or treated with SAG for different durations, were harvested, resuspended in TEEM buffer (32) , and rapidly freeze-thawed thrice and passed through a 26-gauge needle (10 times) for lysis. The lysates were centrifuged (800 ϫ g for 10 min at 4°C), the supernatants were collected, and the proteins were estimated using Bradford reagent. The supernatants were mixed with Laemmli buffer, heated in a boiling water bath for 5 min, and cooled to room temperature. About 20 g of protein was loaded in each lane of sodium dodecyl sulfate-polyacrylamide gels, electrophoresed, and then transferred onto polyvinylidene difluoride membrane. Immunoblotting was performed with appropriately diluted specific primary Abs, and finally chemiluminescence was performed with LumiGlo reagent as described by the manufacturer. Densitometric analyses were done using Quantity1 (Bio-Rad) software.
Assay of cytokines. Uninfected or MHOM/IN/1983/AG83-infected Ms (1 ϫ 10 6 ) were treated with SAG for different durations in a final culture volume of 200 l. The supernatants were collected after centrifugation. Then, TNF-␣ was assayed using an enzyme-linked immunosorbent assay kit according to the manufacturer's protocol.
Statistical analysis. Each experiment was performed three to five times and results are expressed as means Ϯ standard errors of the means (SEM), or Student's t test for significance was performed and a P value of Ͻ0.05 was considered significant. Western blots show representative data from three independent experiments.
RESULTS
SAG-induced generation of ROS and NO in macrophage and control of intracellular parasites. Since ROS and NO are the two major microbicidal molecules (2), we examined whether the antileishmanial effects of SAG were dependent on these two free radicals. It was observed that the amastigotes grew until 24 h after infection in the SAG-untreated I-Ms, whereas in SAG-treated I-Ms the amastigote count steadily declined (Fig. 1A) , suggesting an early control of the parasite load by SAG.
Since pentavalent antimonial treatment in vitro induces ROS generation in human polymorphonuclear cells (48), we studied the ability of SAG to induce ROS in uninfected Ms and I-Ms. We observed that ROS generation was enhanced significantly (P Ͻ 0.001) in uninfected Ms upon SAG treatment. The peak was attained at 3 h, and the level decreased gradually thereafter (Fig. 1B) . Similarly, there was a slight enhancement of NO generation with time in uninfected Ms but this was significantly (P Ͻ 0.001) enhanced upon SAG treatment (Fig. 1C) . When I-Ms were treated with SAG, there was early ROS and late NO generation, which was essentially comparable to observations with SAG-treated uninfected Ms (Fig. 1B and C) . However, there was a slight right shift of the peak of ROS generation, the cause of which is not known (Fig. 1B) . Interestingly, as with starch-elicited Ms, SAG could induce both ROS and NO generation in resident peritoneal Ms and could induce high levels of ROS generation in P388D1 cells (data not shown).
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scavenger of ROS, 1 h prior to SAG treatment; this inhibited the SAG-mediated killing of intracellular L. donovani at 6 h (i.e., when SAG-mediated ROS generation was highest and NO generation was negligible in I-Ms) by more than 60% ( Fig. 2A) . Similar data were also obtained with tocopherol at this time point (unpublished data). For our subsequent experiments concerning ROS generation, we have taken the 6-h posttreatment time point because ROS generation peaked at this point in I-Ms in response to SAG treatment (Fig. 1B) .
Since a significant level of NO was produced at 24 h and 48 h (Fig. 1C) in SAG-treated I-Ms, we assessed the intracellular parasite numbers in the presence or absence of L-NMMA at these time points. Significant (P Ͻ 0.001) inhibition of SAGmediated parasite killing occurred in the presence of L-NMMA at 24 h post-SAG treatment, the action being more pronounced at the 48-h time point (Fig. 2A) . The role of iNOS2 was demonstrated by the lack of an antileishmanial effect of SAG in iNOS-deficient Ms at a later phase of infection in vitro (Fig. 2B) . It has been shown earlier that CD40-induced expression of iNOS2 is mediated by p38 MAPK activation (31) . Therefore, it is quite possible that the SAG-induced NO generation is also dependent on signaling intermediates. Inhibitors of PI3K, PKC, Ras, and ERKs strongly inhibited SAG-induced ROS generation, while inhibitors of PI3K and p38 MAPK strongly inhibited SAG-induced NO generation. Since ROS generation is reported to involve Ras (54), PI3K (14) , PKC (55) , and ERKs (14, 54), we tested whether different inhibitors of these intermediates alter the SAG-induced ROS production in Ms. We observed that treatment of I-Ms with inhibitors of PI3K (i.e., wortmannin), PKC (i.e., calphostin C), Ras (i.e., mevastatin), or MEK (i.e., U0126) prior to SAG treatment strongly inhibited the SAG-induced ROS generation (Fig. 3, top) . Taking the SAG-induced increase in ROS generation over the untreated control value as 100%, the extents of inhibition of ROS generation were ϳ58.5% with wortmannin, ϳ74.16% with calphostin C, ϳ55% with mevastatin, and ϳ71% with U0126. On the other hand, the inhibitor of p38 MAPK (i.e., SB203580) only marginally (ϳ16.6%) inhibited the SAG-induced ROS generation. This study was carried out at 6 h because maximum ROS generation was observed for I-Ms at this time point.
The p38 MAPK has widely been reported to be involved in NO generation (3, 25, 31) , and activation of p38 MAPK is reported to require the involvement of PI3K (25, 30, 52 ). Therefore, we tested with inhibitors of PI3K and p38 MAPK to determine whether SAG involves this pathway to induce NO production in Ms. It was observed that treatment of I-Ms with wortmannin or SB203580 prior to SAG treatment almost completely inhibited the SAG-induced NO generation at 24 h and also inhibited intracellular parasite killing by ϳ94% or ϳ99%, respectively (Fig. 3, bottom) . On the contrary, pretreatment with inhibitors of PKC, Ras, and ERKs had only minor inhibitory effects (ϳ5%, ϳ14.8%, and ϳ18.9%, respectively) on SAG-induced NO production. This study was also conducted at the 48-h time point, and the results obtained were essentially similar to those obtained at the 24-h time point. However, the result for the 24-h time point has been presented because the difference in numbers of intracellular L. donovani parasites between untreated and SAG-treated Ms was maximal at this time point. Altogether, these data suggest that 
FIG. 3. Effect of inhibitors of PI3K (wortmannin)
, PKC (calphostin C), Ras (mevastatin), and ERK (U0126) on SAG-induced generation of ROS and that of inhibitor of p38 MAPK (SB203580) on SAG-induced generation of NO. I-Ms were treated (ϩ) with wortmannin, calphostin C, mevastatin, U0126, or SB203580 prior to SAG treatment. (Top) ROS levels were measured after 6 h of SAG treatment, and corresponding intracellular parasite numbers were also assessed. Pretreatment with wortmannin, calphostin C, mevastatin, or U0126 significantly inhibited SAGmediated ROS generation as well as parasite killing (P Ͻ 0.005). (Bottom) Nitrite levels in cell-free culture supernatant were estimated after 24 h of SAG treatment, and corresponding intracellular parasite numbers were also assessed. Pretreatment with wortmannin or SB203580 significantly inhibited SAG-mediated NO generation as well as parasite killing (P Ͻ 0.001). For both panels, numbers in parentheses show percentages of inhibition of SAG-mediated intracellular parasite killing compared to levels for respective SAG-treated controls. Results are presented as means Ϯ SEM of five independent experiments. As mentioned in Materials and Methods, the inhibitors did not exhibit any cytotoxicity at the doses used in this and subsequent experiments.
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MAPK and p38 MAPK activation pathways (26, 30, 52) . Since PKC ␣ and ␤ are known to be involved in the ERK activation pathway (7, 8) , we tested the phosphorylation of PKC ␣/␤ II in this study. It was observed that SAG treatment of I-Ms for only 30 min induced the phosphorylation of PI3K, PDK1, PKC ␣/␤ II , Raf, and ERKs (Fig. 4) . PI3K phosphorylation increased gradually with an increase in duration of SAG treatment up to 2 h and remained high even up to 24 h. The extent of phosphorylation of PI3K following 2 h of SAG treatment was ϳ4-fold compared to that for the infected control. Phosphorylations of PDK1 and PKC ␣/␤ II were maximal at 30 min post-SAG treatment. The extents of phosphorylation of PDK1 and PKC ␣/␤ II following 0.5 h of SAG treatment were ϳ3-fold and ϳ2.5-fold, respectively, compared to that for the infected control. Thereafter, the phosphorylation level of PKC ␣/␤ II decreased gradually, but the PDK1 phosphorylation was sustained (at an ϳ2-foldhigher level than that for the infected control, even up to 24 h). Interestingly, Raf phosphorylation, which increased gradually from 30 min with an increase in duration of SAG treatment, remained high even up to 2 h of treatment and then decreased gradually. Strong phosphorylation of ERKs was observed up to 2 h of SAG treatment; it decreased and ERK-2 following 1 h and 2 h of SAG treatment were 1.5-fold and ϳ2-fold, respectively, compared to that for the infected control. Phosphorylation of Akt was very weak at 30 min following SAG treatment but increased gradually and reached the peak at about 6 h posttreatment, i.e., when the SAG-induced phosphorylation of PKC ␣/␤ II became very weak. The extent of phosphorylation of Akt following 6 h of SAG treatment was ϳ2-fold compared to that for the infected control. Phosphorylation of p38 MAPK was evident only following 1 h of SAG treatment; it gradually increased up to 6 h and then decreased slightly but persisted even up to 24 h post-SAG treatment (Fig. 4) . The peak of phosphorylation of p38 MAPK was observed to occur following 6 h of SAG treatment, and the extent was ϳ4.5-fold compared to that for the infected control.
To test the probable pathway for SAG-induced phosphorylation of ERKs and p38 MAPK in I-Ms, Western blot experiments were performed with inhibitors of PI3K, PKC, and Ras. We observed that pretreatment with wortmannin completely abrogated SAG-induced PDK1 and PKC ␣/␤ II phosphorylation at 30 min and almost completely inhibited the SAG-induced phosphorylations of Raf and ERKs at 1 h (Fig. 5) . On the other hand, wortmannin pretreatment also completely abrogated SAG-induced phosphorylation of Akt and almost completely inhibited that of p38 MAPK at 6 h (Fig. 5) . Further, pretreatment with calphostin C or mevastatin strongly inhibited SAG-induced phosphorylations of Raf and ERKs at 1 h but not that of Akt or p38 MAPK at 6 h. SAG treatment triggered TNF-␣ production through participation of p38 MAPK. Activation of p38 MAPK is well reported to trigger production of TNF-␣ (29), which is known to induce iNOS2 expression and NO generation (29) . These studies prompted us to investigate the involvement of TNF-␣ in FIG. 5 . PI3K phosphorylation due to SAG treatment induces phosphorylation of PDK1, PKC ␣/␤ II , Raf, and ERK-1/ERK-2 as well as that of Akt and p38 MAPK. I-Ms were treated with an inhibitor of PI3K (wortmannin), PKC (calphostin C), or Ras (mevastatin) for 1 h prior to SAG treatment, and the phosphorylation status of PDK1 and PKC ␣/␤ II at 30 min of SAG treatment, Raf and ERK at 1 h of SAG treatment, and Akt and p38 MAPK at 6 h of SAG treatment (SAG-induced phosphorylation status of each of the above-mentioned signaling molecules was maximal at these time points) was determined by immunoblotting. Phosphorylation status of each of the above-mentioned molecules was expressed as the densitometric ratio of the phosphorylated form (labeled Phospho or P) versus the internal control (␤-actin). Representative data of three similar experiments are presented here.
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the SAG-mediated NO generation due to activation of p38 MAPK. SAG treatment of I-Ms induced TNF-␣ production (Fig. 6A) , and this could be inhibited almost completely by pretreatment with wortmannin or SB203580. On the contrary, pretreatment with an inhibitor of PKC, Ras, or ERKs failed to show any significant inhibition (extent of inhibition was ϳ7.1%, ϳ14.6%, or ϳ12%, respectively) (Fig. 6A) . We then investigated whether the SAG-induced NO production in I-Ms was mediated by TNF-␣. It was observed that incubation of I-Ms with anti-TNF-␣ neutralizing Ab strongly suppressed SAGinduced NO production after 24 h and completely abrogated it 
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on July 23, 2017 by guest http://aac.asm.org/ after 48 h (Fig. 6B) . Furthermore, incubation of I-Ms with anti-TNF-␣ neutralizing Ab also inhibited SAG-induced killing of intracellular L. donovani parasites partially (ϳ60.8%), but significantly (P Ͻ 0.01), at 24 h and completely after 48 h (P Ͻ 0.005) (Fig. 6C) .
DISCUSSION
The present study has provided the first insight into the involvement of signaling intermediates, namely, PI3K, PKC, and MAPKs, in SAG-mediated generation of the leishmanicidal molecules (ROS and NO). Our results show that SAG treatment alone induced both ROS and NO in murine Ms and induced two waves of killing of L. donovani amastigotes. The first phase of killing (i.e., at an early time point, around 6 h posttreatment) was due to induction of ROS, as evident from the sensitivity to tocopherol (data not shown) or NAC, while the second wave of killing (i.e., at later time points, 24 h and 48 h) was mediated by NO generation, as evident from the sensitivity to L-NMMA and failure of SAG to inhibit killing of intracellular L. donovani parasite replication in peritoneal Ms from iNOS Ϫ/Ϫ C57BL/6 mice at 24 h posttreatment. Both ROS and NO are known to be involved in parasite killing in the early stage of leishmanial infection in mice, whereas NO alone is involved in the late phase (39) .
Since the SAG-induced phosphorylation of PKC ␣/␤ II , which occurred by 30 min posttreatment, was observed to be inhibited by wortmannin pretreatment, it is possible that SAG treatment resulted in rapid phosphorylation of PI3K, which is a well-known activator of PDK1 (9, 27) that in turn activates several PKC isotypes (9, 27) . Inasmuch as wortmannin, calphostin C, and mevastatin inhibited the SAG-induced Raf phosphorylation as late as 1 h, our observations present a new mode of Raf activation which is very different from receptor activation-mediated Raf activation and recruitment to the membrane. Our results also suggest that SAG-induced activation of the PI3K-PKC-Ras/Raf pathway triggered ERK phosphorylation. Pretreatment of I-M with any of these inhibitors or U0126 resulted in significant inhibition (P Ͻ 0.01 for wortmannin and mevastatin and P Ͻ 0.005 for calphostin C and U0126) of SAG-mediated ROS generation, suggesting that SAG activates the PI3K-PKC-Ras-ERK pathway and thereby triggers ROS generation.
On the other hand, inhibition of PI3K or p38 MAPK strongly abrogated SAG-mediated NO production in I-Ms as well as parasite killing at ϳ24 h following SAG treatment. This suggested that NO production and subsequent parasite killing in response to SAG treatment involved mainly PI3K and p38 MAPK. The PI3K-Akt-p38 MAPK pathway (25) was shown to be involved in NO generation (25, 26) . Activation of PKC inhibits PI3K-mediated activation of Akt (33) . In our study it has also been observed that although Akt was phosphorylated 1 h following SAG treatment, the level reached a peak at 6 h posttreatment, when phosphorylation of PKC ␣/␤ II was very low. This phosphorylation could be inhibited by wortmannin pretreatment, confirming that SAG-induced prolonged activation of PI3K resulted in Akt phosphorylation. The activation of the PI3K-Akt pathway by SAG seemed to trigger phosphorylation of p38 MAPK that was almost completely abrogated by wortmannin pretreatment. The PKC-Ras pathway played a minimal role in SAG-induced p38 MAPK phosphorylation, as it was insensitive to pretreatment with calphostin C or mevastatin.
L. donovani infection has been reported to increase protein tyrosine phosphatase activity, mainly that of type SHP1 (5, (44) (45) (46) , which might contribute to dysregulation of protein tyrosine kinase-dependent signaling events and M deactivation (44) . SHP1 might directly dephosphorylate ERKs (45) and regulate activation of other important signaling molecules, like PI3K (12) . Thus, inhibition of SHP1 by SAG might indirectly favor the tyrosine phosphorylation of PI3K and might thereby help in activating both the PI3K-PKC-Ras/Raf-ERK-1/ERK-2 pathway for ROS generation and the PI3K-Akt-p38 MAPK pathway leading to NO generation.
The p38 MAPK has been shown to induce TNF-␣ production (29) , which in turn induces iNOS2 expression and subsequent NO generation (29) , as suggested by the inhibition of NO generation and parasite killing by treatment with anti-TNF-␣ neutralizing Ab. The SAG-mediated TNF-␣ generation could be inhibited by wortmannin or SB203580 pretreatment, indicating that SAG-induced activation of the PI3K-p38 MAPK pathway not only activates NO-mediated parasite control but also reinforces the mechanism by triggering endogenous TNF-␣ that controls the parasite in an autocrine manner. Indeed, the SAGinduced antileishmanial activity is reduced in TNF-␣ knockout mice (35) . In addition, since SAG up-regulates IFN-␥ receptors in both uninfected and L. donovani-infected THP-1 cells, as well as in monocytes derived from kala-azar patients treated with SAG (13), it is quite possible that SAG influences the host's antileishmanial defense by altering IFN-␥ responsiveness. Indeed, SAG fails to act in IFN-␥ knockout mice (40) , and in the case of chronic, nonhealing murine cutaneous leishmaniasis, treatment with SAG plus IFN-␥ induces much higher levels of iNOS2 transcripts in footpad tissues than SAG or IFN-␥ alone (28) . We have also observed that SAG and IFN-␥ synergize to produce high levels of NO in Ms (unpublished data). A combination of SAG and IFN-␥ is also known to be therapeutically much more effective than SAG alone in the treatment of visceral leishmaniasis (37) . We have further observed that SAG triggers production of IL-12 in both uninfected Ms and I-Ms (unpublished data). IL-12 is known to induce Th cells to produce IFN-␥, which in turn activates Ms to produce TNF-␣ and, subsequently, NO. This might explain the failure of SAG to act in IL-12 knockout mice, as reported in earlier studies (41) . Furthermore, an earlier study showed that SAG treatment of infected mice imparted resistance to reinfection whereas SAG treatment prior to infection imparted partial resistance to L. donovani infection (10) . All of these results may explain the requirement of T cells for the activity of SAG in vivo (36) . Interestingly, neither sodium gluconate (i.e., the organic backbone of SAG) nor inorganic Sb V (SbCl 5 ) could induce significant levels of ROS or NO generation and parasite killing in I-Ms, while SbCl 5 (at 10 g Sb V equivalent) proved to be highly cytotoxic (unpublished data), suggesting that neither the backbone nor the metalloid alone has the immunomodulatory effect shown by SAG (an organic chelate of Sb V ). Therefore, the use of SAG in combination therapy (either with other drugs or possibly with vaccines) may prove beneficial. Moreover, our preliminary observations indicate that resistance to antimonials occurred mainly due to overexpression 
